New Mechanisms and Expanded Indications for Biologic Therapies: a Perspective on Immunology Research and Development

Total Page:16

File Type:pdf, Size:1020Kb

New Mechanisms and Expanded Indications for Biologic Therapies: a Perspective on Immunology Research and Development New mechanisms_Layout 1 27/09/2010 13:57 Page 87 Therapeutics New mechanisms and expanded indications for biologic therapies: a perspective on immunology research and development Over the past decade, the introduction of biologic therapies has had a profound impact for millions of patients with immune-mediated arthritides, inflammatory bowel diseases and plaque psoriasis. Today, five anti-Tumor Necrosis Factor (TNF) therapies are approved in the United States and many countries around the world, and innovations in the TNF class continue more than a decade after the initial approval. Several other biologic therapies targeting distinct immune cell receptors or cytokines have been approved for immunologically mediated diseases, and many promising new biologic medicines are in various stages of clinical development. n this article I will provide an overview of adalimumab (HUMIRA®) for rheumatoid arthri- By Dr Susan B. Dillon some of the current trends influencing the tis (RA) in 1998 and 2002, respectively, the devel- I development of new biologics for immune- opment of anti-TNF biologics has continued. mediated and inflammatory diseases including Infliximab is now approved for 15 indications in 1) the continued clinical development of biologics the US (Table 1)1. In 2009, golimumab (SIM- targeting TNF-␣; 2) new mechanisms in inflamma- PONI®), a human monoclonal antibody (mAb) tion that are being explored in clinical trials and with once-monthly subcutaneous (SC) dosing 3) recent advances in the application of new bio- received approvals for RA, psoriatic arthritis logic therapies to an expanded list of indications (PsA) and ankylosing spondylitis (AS). Another with high unmet medical need. agent, certolizumab (CIMZIA®) was also approved for RA in 2009, bringing the total num- Continued development of TNF ber of approved anti-TNF therapies to five agents biologics for immune-mediated disease (Table 2)2-5. Thus, it has been firmly established Since the initial approval of infliximab (REMI- that TNF is an important pathogenic mediator in CADE®) for Crohn’s disease in 1998 and the sub- a number of autoimmune and inflammatory dis- sequent approvals of etanercept (ENBREL®) and eases, a fact that was not fully appreciated before Drug Discovery World Fall 2010 87 New mechanisms_Layout 1 27/09/2010 13:57 Page 88 Therapeutics Table 1: Infliximab approved indications1 predict the likelihood that an individual will have both an initial and durable response to anti-TNF DATE INDICATION therapy. A variety of potential demographic, clini- cal, radiological, blood, genetic or synovial tissue 1998 Crohn’s disease – luminal and fistulising markers has been studied. High local (synovial) and systemic levels of TNF-␣ appear to be corre- 1998 Rheumatoid arthritis signs and symptoms (MTX failures) lated with good clinical response although valida- tion by further studies is needed8,9. 2000 Rheumatoid arthritis structural damage Molecular profiling and genetic association (MTX failures) studies have potential for identification of markers which predict response to treatment. While these 2002 Rheumatoid arthritis physical function approaches have produced tantalising results, pub- (MTX failures) lished studies to date have been small and remain to be prospectively validated in large clinical 2002 Crohn’s disease maintenance (luminal) cohorts10-12. The paradigm of identifying respon- 2003 Crohn’s disease maintenance (fistulising) der populations may also be applicable to inflam- matory bowel diseases, where gene expression sig- 2004 Rheumatoid arthritis signs and symptoms, natures have been identified that correlate to TNF- x-ray progression, physical function ␣ response and non-response in ulcerative colitis (MTX naïve) (UC) patients treated with infliximab13. 2004 Ankylosing spondylitis signs and symptoms The failure of many patients to initially respond or maintain a response to therapy with an anti- 2005 Psoriatic arthritis signs and symptoms TNF agent has also led to research into the poten- tial of switching within the class. Patients who fail 2005 Ulcerative colitis to respond to one or more anti-TNF therapies may respond to another, as was demonstrated by results 2006 Pediatric Crohn’s disease of the G0-AFTER study of golimumab in RA 2006 Psoriatic arthritis structural damage patients previously treated with one or more TNF inhibitors14. More than a third of the patients 2006 Psoriatic arthritis physical function whose prior anti-TNF therapy had been discontin- ued due to lack of efficacy achieved an ACR20 2006 Chronic severe plaque psoriasis response to golimumab. A recent report of infliximab in the Study of 2006 Ulcerative colitis maintenance Biologic and Immunomodulator Naïve Patients in Phase III Pediatric ulcerative colitis Crohn’s (SONIC) compared infliximab, azathio- prine and the combination of both drugs in Indications refer to approvals from the Food and Drug Administration (FDA) for the US only patients with moderate to severe Crohn’s disease who had not received prior immunosuppressive or biologic therapies. Patients receiving infliximab- the era of anti-TNF biologic therapies. Even with containing regimens were more likely to experience these advances, however, there is still great poten- clinical remission without the use of steroids and tial for further innovations with the TNF class. demonstrated improved mucosal healing15. Based In RA, approximately 60% of biologic naïve on this landmark study, the American College of patients with an inadequate response to disease Gastroenterology guidelines on the management of modifying anti-rheumatic drugs (DMARDs) Crohn’s disease now recommend infliximab with (depending on the specific patient population, ther- or without azathioprine as more effective than aza- apeutic, trial design and other variables) achieve a thioprine alone in the treatment of patients with 20% improvement in disease activity according to moderate to severe Crohn’s disease who have failed the American College of Rheumatology criteria to respond to first-line steroid or 5-aminosalicylic (ACR20) with anti-TNF treatment6, and even acid (5-ASA) therapy16. fewer (less than 20%7) achieve clinical remission, Anti-TNF agents have transformed treatment of defined as maintenance of an ACR70 response for immune disease. After more than a decade of suc- at least six months. This, and the fact that many cessful application of anti-TNF treatment in a mul- patients lose response over time, has prompted titude of inflammatory diseases, we continue to research into the identification of biomarkers to study and to learn more about these drugs. Clinical 88 Drug Discovery World Fall 2010 New mechanisms_Layout 1 27/09/2010 13:57 Page 90 Therapeutics investigations are currently under way in new indi- bodies and receptor fusion proteins with alterna- cations and to extend use paradigms in approved tive (non-TNF-␣) mechanisms that have received indications. Basic research studies continue to approvals in many of the same indications for define exactly how these agents work to modulate which infliximab was approved. Rather than dis- the immune system, and biomarker efforts are in cuss the mechanisms for these therapeutics, which progress to identify predictive markers of response. are extensively reviewed elsewhere, this report will All of these investigations provide new data to focus on new mechanisms in clinical development. optimise and extend usage of these powerful ther- Cytokines involved in both innate immune apeutic agents. responses and in the regulation of B and T lym- phocyte adaptive immune responses, such as IL-12, Targeting new mechanisms in IL-23, IL-17 and IL-6, have become the focus for inflammation new antibody targets. IL-12 was initially identified The successes achieved with anti-TNF biologics for as a factor involved in several immune activities the treatment of a collection of immune-mediated including the induction of cytotoxic T lymphocytes diseases impacting the joints, intestinal tract and (CTL) and lymphokine-activated killer cells skin have encouraged the search for new therapeu- (LAKs) and the augmentation of natural killer cell tic targets that may impact these organ systems and mediated toxicity21,22, and it is now recognised as others that are affected in immunologic disorders. an important cytokine in driving differentiation of TNF-␣ is produced by multiple cell types, most Th1 cells. The hallmark cytokine produced by Th1 notably by macrophages as part of the innate cells, Interferon ␥, along with TNF-␣, play an immune response to pathogens and other inflam- important role in protecting against infection and matory stimuli. In addition to playing an impor- in contributing to autoimmune disease pathology. tant role in host defence against infection and can- The more recent discovery of the IL-12 family cer, TNF-␣ has many biologic activities that pro- member IL-23 was crucial to the identification of mote inflammation, including increasing the Th17 cells, which also contribute to autoimmuni- expression of adhesion molecules (ICAM, VCAM) ty23. The genetic and human translational studies on keratinocytes and endothelial cells17, inducing implicating Th1 and Th17 cells in diseases has led the expression of other inflammatory cytokines to the focus on antibodies blocking the activities of (such as IL-1, IL-6 and, IL-8)18, and inducing IL-12, IL-23 and IL-17. VEGF expression, which increases angiogenesis at sites of inflammation19. All of these activities have IL-12/IL-23 the combined effect of increasing
Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Of Anti-CD3 Action? This Information Is Current As of September 26, 2021
    Differential Response of Regulatory and Conventional CD4 + Lymphocytes to CD3 Engagement: Clues to a Possible Mechanism of Anti-CD3 Action? This information is current as of September 26, 2021. Li Li, Junko Nishio, André van Maurik, Diane Mathis and Christophe Benoist J Immunol published online 28 August 2013 http://www.jimmunol.org/content/early/2013/08/27/jimmun ol.1300408 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/28/jimmunol.130040 Material 8.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published August 28, 2013, doi:10.4049/jimmunol.1300408 The Journal of Immunology Differential Response of Regulatory and Conventional CD4+ Lymphocytes to CD3 Engagement: Clues to a Possible Mechanism of Anti-CD3 Action? Li Li,* Junko Nishio,* Andre´ van Maurik,† Diane Mathis,* and Christophe Benoist* Several clinical trials have shown anti-CD3 treatment to be a promising therapy for autoimmune diabetes, but its mechanism of action remains unclear.
    [Show full text]
  • Report, Please Call the Telephone Number Listed
    201R1e port M E D I C I N E S I N D E V E L O P M E N T F O R Arthritis P R E S E N T E D B Y A M E R I C A ’ S B I O P H A R M A C E U T I C A L R E S E A R C H C O M P A N I E S Biopharmaceutical Research Companies are Developing Nearly 200 Medicines for the Most Common Chronic Health Problem in the United States merica’s biopharmaceutical research companies are MEDICINES AND VACCINES IN DEVELOPMENT FOR ARTHRITIS* currently developing 198 medicines to help the Behcet’s Syndrome 3 more than 50 million Americans afflicted with at A Duchenne Muscular Dystrophy 6 least one of the 100 different musculoskeletal disorders, Fibromyalgia 9 including arthritis. All of the medicines are either in Gout 7 clinical trials or awaiting review by the U.S. Food and Lupus 19 Muscle Disorders 11 Drug Administration. Osteoarthritis 19 Osteoporosis 23 Arthritis is the most common cause of disability in the Pain 15 United States. Each year, it is responsible for 44 million Psoriatic Arthritis 7 outpatient doctor visits, nearly 1 million hospitalizations, Raynaud’s Disease 4 and nearly 10,000 deaths. And it costs the American Rheumatoid Arthritis 67 Scleroderma 6 economy nearly $128 billion annually in direct medical Spondylitis 7 costs and indirect costs, such as lost wages and Other 22 productivity. * Some medicines are listed in more than one category.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Insulin Is Necessary but Not Sufficient: Changing the Therapeutic Paradigm in Type 1 Diabetes [Version 1; Peer Review: 5 Approved] Sandra Lord , Carla J
    F1000Research 2020, 9(Faculty Rev):827 Last updated: 30 JUL 2020 REVIEW Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes [version 1; peer review: 5 approved] Sandra Lord , Carla J. Greenbaum Benaroya Research Institute at Virginia Mason, Seattle, WA, 98101, USA First published: 30 Jul 2020, 9(Faculty Rev):827 Open Peer Review v1 https://doi.org/10.12688/f1000research.21801.1 Latest published: 30 Jul 2020, 9(Faculty Rev):827 https://doi.org/10.12688/f1000research.21801.1 Reviewer Status Abstract Invited Reviewers Despite the clear evidence that type 1 diabetes (T1D) begins well before 1 2 3 4 5 hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of version 1 the Teplizumab Prevention Study, the first study to demonstrate that overt 30 Jul 2020 T1D can be delayed with immunotherapy, there is renewed optimism that in the future, T1D will be treated before hyperglycemia develops. A different treatment paradigm is needed, as a majority of people with T1D do not meet the glycemic targets that are associated with a lower risk of T1D Faculty Reviews are review articles written by the complications and therefore remain vulnerable to complications and prestigious Members of Faculty Opinions. The shortened life expectancy. The following review will outline the history and articles are commissioned and peer reviewed before current status of immunotherapy for T1D and highlight some challenges publication to ensure that the final, published version and ideas for the future. Although such efforts have been worldwide, we will focus particularly on the activities of Diabetes TrialNet, a National Institutes is comprehensive and accessible.
    [Show full text]
  • Modulating Igg Effector Function by FC Engineering and Glycoengineering Andy Racher † & Olga Obrezanova ‡
    Modulating IgG effector function by FC engineering and glycoengineering Andy Racher † & Olga Obrezanova ‡ Lonza Biologics, 228 Bath Road, Slough, Berkshire, SL1 4DX, UK † Corresponding author: [email protected] ‡ Current address: AstraZeneca, Cambridge, UK 2 Summary several Fc engineered and glycoengineered antibodies in late stage clinical trials. Several proprietary technologies were Antibodies are the fastest growing group of biotherapeutics. In developed for glycoengineering of monoclonal antibodies early 2020 more than 100 antibody-based molecules, including including Potelligent® technology (KHK / BioWa), GlycoMAb® biosimilars, had been approved globally. Oncology and (GlycArt / Roche), EMABLing® (LFB), GlycoExpress™ (Glycotope) inflammatory disorders remain the major therapeutic areas for and GlymaxX® (ProBioGen). antibody-based molecules but there is a growing interest in using mAbs for treating infectious disease. During the last 10 Encouraging clinical results and prospects in multiple disease years antibody engineering focussed on development of “fit- areas make it likely that more Fc engineered and for-purpose” antibodies with modulated effector functions glycoengineered antibodies will enter clinical trials and such as increased or muted antibody-dependent cell-mediated subsequently be approved. According to market research cytotoxicity (ADCC), antibody-dependent cellular phagocytosis studies, the glycoengineered antibodies are likely to emerge as (ADCP), complement dependent cytotoxicity (CDC), and to the forerunner in the short term (84% of the market share by increase half-life. This paper summarises approaches for 2021) and, subsequently, the Fc protein engineered antibodies modulating antibody effector functions and pharmacokinetics, are likely to gain a higher proportion (55% by 2026). and provides examples of antibodies in clinical studies Glycoengineering strategies focussing on enhancing ADCC employing such approaches.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • 826.Full.Pdf
    Emerging Treatments and Technologies ORIGINAL ARTICLE Failure to Preserve ␤-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes 1 6 PETER A. GOTTLIEB, MD DESMOND A. SCHATZ, MD tions Trial (DCCT) demonstrated that im- 2 7 SCOTT QUINLAN, MS ANTOINETTE M. MORAN, MD proved metabolic control reduces chronic 2 2 HEIDI KRAUSE-STEINRAUF, MS JOHN M. LACHIN, SCD 3 8 complications in type 1 diabetes (5). A CARLA J. GREENBAUM, MD JAY S. SKYLER, MD 4 post hoc analysis of DCCT found that DARRELL M. WILSON, MD FOR THE TYPE 1DIABETES TRIALNET 5 those with residual ␤-cell function, man- HENRY RODRIGUEZ, MD MMF/DZB STUDY GROUP* ifested by C-peptide values Ͼ0.2 pmol/ ml, had both less hypoglycemia and fewer complications than those without resid- OBJECTIVE — This trial tested whether mycophenolate mofetil (MMF) alone or with dacli- ␤ ual function (6). Thus an intervention zumab (DZB) could arrest the loss of insulin-producing -cells in subjects with new-onset type that prolongs ␤-cell function would be 1 diabetes. expected to improve metabolic control RESEARCH DESIGN AND METHODS — A multi-center, randomized, placebo- and reduce complications (7). controlled, double-masked trial was initiated by Type 1 Diabetes TrialNet at 13 sites in North Mycophenolic acid (MPA) was dis- America and Europe. Subjects diagnosed with type 1 diabetes and with sufficient C-peptide covered in 1896 and characterized in within 3 months of diagnosis were randomized to either MMF alone, MMF plus DZB, or placebo, 1952. Mycophenolate mofetil (MMF) is and then followed for 2 years.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub
    US 20150250896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub. Date: Sep. 10, 2015 (54) HYDROPHILIC LINKERS AND THEIR USES Publication Classification FOR CONUGATION OF DRUGS TO A CELL (51) Int. Cl BNDING MOLECULES A647/48 (2006.01) (71) Applicant: Yongxin R. ZHAO, Henan (CN) Ek E. 30.8 C07D 207/216 (2006.01) (72) Inventor: R. Yongxin Zhao, Lexington, MA (US) C07D 40/12 (2006.01) C07F 9/30 (2006.01) C07F 9/572 (2006.01) (73) Assignee: Hangzhou DAC Biotech Co., Ltd., (52) U.S. Cl. Hangzhou City, ZJ (CN) CPC ........... A61K47/48715 (2013.01); C07F 9/301 (2013.01); C07F 9/65583 (2013.01); C07F (21) Appl. No.: 14/432,073 9/5721 (2013.01); C07D 207/46 (2013.01); C07D 401/12 (2013.01); A61 K3I/454 (22) PCT Filed: Nov. 24, 2012 (2013.01) (86). PCT No.: PCT/B2O12/0567OO Cell(57) binding- agent-drugABSTRACT conjugates comprising hydrophilic- S371 (c)(1), linkers, and methods of using Such linkers and conjugates are (2) Date: Mar. 27, 2015 provided. Patent Application Publication Sep. 10, 2015 Sheet 1 of 23 US 2015/0250896 A1 O HMDS OSiMe 2n O Br H-B-H HPC 3 2 COOEt essiop-\5. E B to NH 120 °C, 2h OsiMe3 J 50 °C, 2h eSiO OEt 120 oC, sh 1 2 3. 42% from 1 Bra-11a1'oet - Brn 11-1 or a 1-1 or ÓH 140 °C ÓEt ÓEt 4 5 6 - --Messio. 8 B1a-Br aus 20 cc, hP-1}^-'ot Br1-Y.
    [Show full text]
  • Anti-CD3 Drug Keeps Diabetes at Bay No Drug Has Ever Delayed Islet Cell Destruction
    news IN this section β-thalassemia Gilead, Galapagos Biotech news from gene therapy in $5.1 billion tie around the world approved p1102 p1104 p1106 Anti-CD3 drug keeps diabetes at bay No drug has ever delayed islet cell destruction. Now that teplizumab has, the challenge turns to identifying eligible recipients for the treatment. he first drug to ever slow the progression from pre-diabetes to Tclinical type 1 diabetes is one step closer to reaching the market. On August 5, the US Food and Drug Administration (FDA) granted breakthrough therapy designation to teplizumab, a CD3-targeted antibody from Provention Bio, to prevent or delay type 1 diabetes onset among children and adults at high risk of developing the disease. The regulatory distinction comes after a June report showing that teplizumab postponed the onset of symptomatic disease by a median of two years compared with placebo in patients who took the drug for 14 days (N. Engl. J. Med. 381, 608–613, 2019). “It’s a very prolonged effect after a single two-week course of the antibody,” says Lucienne Chatenoud, an immunologist from the Necker Hospital for Sick Children in Paris who was not involved in the study. “This is, in view of all clinical diabetologists, a real measure Should a treatment to push back the age of type 1 diabetes onset become available, screening programs of robustness... You are really delaying the to identify children at a markedly elevated risk will be critical. One such European effort is the Global onset of insulin therapy.” Platform for the Prevention of Autoimmune Diabetes, which has undertaken to screen 100,000 Although some researchers maintain newborns for disease-associated variants, including polymorphisms in human leukocyte antigens (HLA) that larger confirmatory trials are still of the DR and DQ isotypes.
    [Show full text]